Short answer
CYTOKINETICS INC (CYTK) filed an 8-K current report with the SEC on May 5, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Exhibit 99.1 contains Cytokinetics’ corporate presentation, likely providing updated business or pipeline information.
CYTOKINETICS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Exhibit 99.1 contains Cytokinetics’ corporate presentation, likely providing updated business or pipeline information
- Filing dated May 5, 2026 and signed by SVP, Deputy General Counsel & Secretary John O. Faurescu
Item EX-99.1 · Exhibit EX-99.1
- ~$1.1B cash, equivalents and investments as of 3/31/26, supporting commercial expansion and pipeline development
- MYQORZO launched in January 2026 for symptomatic oHCM in the U.S. and China, with EU launch expected in Germany during Q2 2026
- More than 1,100 patients had paid MYQORZO prescriptions by 4/30/26, up from 680 at 3/31/26
- Aficamten sNDA under FDA review, with PDUFA decision targeted for November 14, 2026
- ACACIA-HCM met primary endpoints in nHCM, with pVO₂ benefit of 0.67 mL/kg/min and KCCQ-CSS benefit of 3.0 points versus placebo
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CYTOKINETICS INC 8-K filings
Get the next CYTK 8-K as it lands
Follow CYTK for push alerts, or ask the research agent what this filing means.